1.Banta, D. The development of health technology assessment. Health Policy. 2003;63:121–132.
2.Battista, RN. Towards a paradigm for technology assessment. In: Peckham, M, Smith, R, eds. The scientific basis of health services. London: BMJ Publishing Group; 1996.
3.Claxton, K, Ginnelly, L, Sculpher, M, et al. A pilot study on the use of decision theory and value of information analysis as part of the NHS health technology assessment programme. Health Technol Assess. 2004;8:1–103.
4.Eckermann, S, Willan, AR. Expected value of information and decision making in HTA. Health Econ. 2007;16:195–209.
5.Factors CMS Considers in Making a Determination of Coverage with Evidence Development. Draft Guidance. Centers for Medicare and Medicaid Services, April 7, 2005.
6.Granados, A. Health technology assessment and clinical decision making: Which is the best evidence? Int J Technol Assess Health Care. 1999;15:585–614.
7.Granados, A, Borras, JM. Technology assessment in Catalonia: Integrating economic appraisal. Soc Sci Med. 1994;38:1643–1646.
8.Jonsson, E, Banta, HD. Management of health technologies: An international view. BMJ. 319:1293.
9.Laupacis, A. Incorporating economic evaluations into decision-making: The Ontario experience. Med Care. 2005;43:15–19.
10.McCabe, C, Tsuchiya, A, Claxton, K, et al. Drugs for exceptionally rare diseases: A commentary on Hughes et al. Discussion Paper 06/2. Sheffield: The University of Sheffield, ScHARR; 2006.
11.Mowatt, G, Bower, DJ, Brebner, JA, et al. When and how to assess fast-changing technologies: A comparative study of medical applications of four generic technologies. Health Technol Assess. 1997; 1: i-vi,1–149.
12.MSAC Brochure. Medical Services Advisory Committee, Department of Health and Ageing 2007. Available at: www.msac.gov.au.
13.National coverage determinations with data collection as a condition of coverage: Coverage with evidence development. Guidance for the Public, industry and CMS Staff. Centers for Medicare and Medicaid Services, December 12, 2007.
14.Niezen, M, de Bont, A, Stolk, E, et al. Conditional reimbursement within the Dutch drug policy. Health Policy. 2007; 3: doi:10.1016/j.healthpol.2006.11.005.
15.O'Brien, BJ, Gertsen, K, Willan, AR, et al. “Is there a kink in consumers’ threshold value for cost-effectiveness in health care? Health Econ. 2002; 11:175–180.
16.Stocking, B. Factors influencing the effectiveness of mechanisms to control medical technology. In: Stocking, B, ed. Expensive health technologies. Oxford: Oxford University Press; 1988.
17.Tunis, SR, Pearson, SD. Coverage options for promising technologies: Medicare's ‘coverage with evidence development’. Health Aff (Millwood). 2006;25:1218–1230.